Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 5305 |
| PDBID: | 7WBH |
| Chains: | OQ_B |
| Organism: | Severe acute respiratory syndrome-related coronavirus, Homo sapiens |
| Method: | EM |
| Resolution (Å): | 3.70 |
| Reference: | 10.1038/s41392-022-00879-2 |
| Antibody | |
| Antibody: | hu33 Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | SARS-CoV-2 Beta spike glycoprotein |
| Antigen mutation: | No |
| Durg Target: | P0DTC2 |
Sequence information
Antibody
Heavy Chain: O
Mutation: NULL
| >7WBH_O|Chain D[auth O], F[auth P], H[auth U]|heavy chain of hu33|Homo sapiens (9606) QVQLVQSGSELKKPGASVKVSCKASGYTFTDYGMNWVRQAPGQGLEWMGWINTYSGEPTYADDFRGRFVFSLDTSVSTAYLQICSLKAEDTAVYYCARGGNWDWYFDVWGQGTLVTVS |
Light Chain: Q
Mutation: NULL
| >7WBH_Q|Chain E[auth Q], G[auth S], I[auth V]|light chain of hu33|Homo sapiens (9606) DIQMTQSPSSLSASVGDRVTITCRASQSVSNFLHWYQQKPGKAPKLLIYYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNTWPLTFGQGTKLEIK |
Antigen
Chain: B
Mutation: NULL
| >7WBH_B|Chain B, C|Spike glycoprotein|Severe acute respiratory syndrome-related coronavirus (694009) AYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSPIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGPALQIPFPMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTPSALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELD |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| O: THR30 ASP31 TYR32 TRP50 ASN52 TYR54 GLU57 THR59 ASP62 ASN101 TRP102 ASP103 TRP104 Q: GLN27 SER28 PHE32 TYR50 SER91 ASN92 THR93 TRP94 LEU96 B: PRO337 GLY339 GLU340 ASN343 ALA344 THR345 ARG346 LYS356 ASN439 ASN440 LEU441 SER443 LYS444 VAL445 ASN448 TYR449 ASN450 TYR451 PRO499 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
